Predictors of cancer progression in T1a prostate adenocarcinoma
BACKGROUND The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk of can...
Gespeichert in:
| Veröffentlicht in: | Cancer 1999-03, Vol.85 (6), p.1300-1304 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1304 |
|---|---|
| container_issue | 6 |
| container_start_page | 1300 |
| container_title | Cancer |
| container_volume | 85 |
| creator | Cheng, Liang Bergstralh, Erik J. Scherer, Beth G. Neumann, Roxann M. Blute, Michael L. Zincke, Horst Bostwick, David G. |
| description | BACKGROUND
The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk of cancer progression are needed to stratify patients for treatment. In the current study the authors attempted to identify such predictors of cancer progression in a large series of untreated patients with lengthy follow‐up.
METHODS
The authors studied 102 patients who were diagnosed with T1a prostate adenocarcinoma (incidental tumor involving ≤ 5% of the resected prostatic tissue) at the time they underwent transurethral resection of the prostate (TURP) at the Mayo Clinic between 1960–1970. None of these patients were treated. Patient ages ranged from 48–91 years (mean ± standard deviation, 69 ± 7 years). The average weight of the resected prostate tissue was 24 ±18 g (range, 3–115 g; median, 18 g). Tumor volume was measured by the grid method. Cox proportional hazards models were used to identify factors associated with cancer progression. Survival curves were estimated using the Kaplan‐Meier method.
RESULTS
Five‐year and 10‐year progression free survival rates were 93% and 87%, respectively. During the mean follow‐up of 9.5 ± 6.8 years (range, 0.3–31 years; median, 9.0 years), 14 patients developed clinical cancer progression, including 5 patients with systemic progression (1 with distant metastases and 4 who died of prostate adenocarcinoma). The interval from diagnosis to clinical cancer progression ranged from 1–23 years (mean, 7.3 years). The amount of resected prostate tissue (TURP weight) was associated with progression (P = 0.04). Patients with a TURP weight ≥ 30 g had 100% progression free survival at 10 years compared with a progression free survival rate of 73% in patients with a TURP weight < 12 g. Gleason score, tumor volume, number of chips involved by tumor, number of tumor foci, and the presence of high grade prostatic intraepithelial neoplasia were not significant in predicting cancer progression. There was a trend toward a worse prognosis with the increasing number of chips involved by cancer (P = 0.16). Patients with < 3 chips involved by cancer had a 88% 10‐year progression free survival rate compared with 73% in patients with ≥ 3 chips involved by cancer.
CONCLUSIONS
The clinical course of T1a prostate adenocarcinoma is variable. If left untreat |
| doi_str_mv | 10.1002/(SICI)1097-0142(19990315)85:6<1300::AID-CNCR12>3.0.CO;2-# |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69663019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69663019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3302-800d05c298efd26227128086ab93a76265b550af683f01e861099e1b784e5bb63</originalsourceid><addsrcrecordid>eNqFkF2L1DAUQIMo7uzqX5CCIrsPHe9NJmkyyspQvwYWR3RFfbqkaSpdOu2azCD7703p-AEKPoUbTi4nh7EVwhwB-JPTD-tyfYZgihxwwU_RGAMC5ZmWS_UMBcByuVq_yMu35Xvk52IO83LzlOcPb7HZr1e32QwAdC4X4vMRO47xKo0Fl-IuO0JAbVDIGXv-Lvi6dbshxGxoMmd750N2HYavwcfYDn3W9tkl2vEq7uzOZ7b2_eBscG0_bO09dqexXfT3D-cJ-_jq5WX5Jr_YvF6Xq4vcCQE81wA1SMeN9k3NFecFcg1a2coIWyiuZCUl2EZp0QB6rdI3jMeq0Asvq0qJE_Z42ps8vu193NG2jc53ne39sI-kjFIC0CTw0wS6JByDb-g6tFsbbgiBxrpEY10aO9HYiX7WJS1J0ViXKNWlqS4JAio3xNPmBweFfbX19R97p5gJeHQAbHS2a0KK2cbfXJH8iiJhXybse9v5m7_0_m_3D7nDLH4Ag7mfwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69663019</pqid></control><display><type>article</type><title>Predictors of cancer progression in T1a prostate adenocarcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>Cheng, Liang ; Bergstralh, Erik J. ; Scherer, Beth G. ; Neumann, Roxann M. ; Blute, Michael L. ; Zincke, Horst ; Bostwick, David G.</creator><creatorcontrib>Cheng, Liang ; Bergstralh, Erik J. ; Scherer, Beth G. ; Neumann, Roxann M. ; Blute, Michael L. ; Zincke, Horst ; Bostwick, David G.</creatorcontrib><description>BACKGROUND
The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk of cancer progression are needed to stratify patients for treatment. In the current study the authors attempted to identify such predictors of cancer progression in a large series of untreated patients with lengthy follow‐up.
METHODS
The authors studied 102 patients who were diagnosed with T1a prostate adenocarcinoma (incidental tumor involving ≤ 5% of the resected prostatic tissue) at the time they underwent transurethral resection of the prostate (TURP) at the Mayo Clinic between 1960–1970. None of these patients were treated. Patient ages ranged from 48–91 years (mean ± standard deviation, 69 ± 7 years). The average weight of the resected prostate tissue was 24 ±18 g (range, 3–115 g; median, 18 g). Tumor volume was measured by the grid method. Cox proportional hazards models were used to identify factors associated with cancer progression. Survival curves were estimated using the Kaplan‐Meier method.
RESULTS
Five‐year and 10‐year progression free survival rates were 93% and 87%, respectively. During the mean follow‐up of 9.5 ± 6.8 years (range, 0.3–31 years; median, 9.0 years), 14 patients developed clinical cancer progression, including 5 patients with systemic progression (1 with distant metastases and 4 who died of prostate adenocarcinoma). The interval from diagnosis to clinical cancer progression ranged from 1–23 years (mean, 7.3 years). The amount of resected prostate tissue (TURP weight) was associated with progression (P = 0.04). Patients with a TURP weight ≥ 30 g had 100% progression free survival at 10 years compared with a progression free survival rate of 73% in patients with a TURP weight < 12 g. Gleason score, tumor volume, number of chips involved by tumor, number of tumor foci, and the presence of high grade prostatic intraepithelial neoplasia were not significant in predicting cancer progression. There was a trend toward a worse prognosis with the increasing number of chips involved by cancer (P = 0.16). Patients with < 3 chips involved by cancer had a 88% 10‐year progression free survival rate compared with 73% in patients with ≥ 3 chips involved by cancer.
CONCLUSIONS
The clinical course of T1a prostate adenocarcinoma is variable. If left untreated, a small but significant proportion of patients are at risk for disease progression and death. However, the current study found that patients with a TURP weight ≥ 30 g have an excellent prognosis and can be managed conservatively. Cancer 1999;85:1300–4. © 1999 American Cancer Society.
The clinical course of patients with T1a prostate adenocarcinoma is variable. If left untreated, a small but significant proportion of patients are at risk for cancer progression and death. Patients with a transurethral resection tissue weight ≥ 30 g have an excellent prognosis and can be managed conservatively.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1300::AID-CNCR12>3.0.CO;2-#</identifier><identifier>PMID: 10189135</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Disease Progression ; Disease-Free Survival ; Humans ; incidental ; Male ; Medical sciences ; Middle Aged ; natural history ; Nephrology. Urinary tract diseases ; Prognosis ; progression ; Prostate ; Prostatectomy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Survival Rate ; T1a ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Cancer, 1999-03, Vol.85 (6), p.1300-1304</ispartof><rights>Copyright © 1999 American Cancer Society</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3302-800d05c298efd26227128086ab93a76265b550af683f01e861099e1b784e5bb63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819990315%2985%3A6%3C1300%3A%3AAID-CNCR12%3E3.0.CO%3B2-%23$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819990315%2985%3A6%3C1300%3A%3AAID-CNCR12%3E3.0.CO%3B2-%23$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1701977$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10189135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Bergstralh, Erik J.</creatorcontrib><creatorcontrib>Scherer, Beth G.</creatorcontrib><creatorcontrib>Neumann, Roxann M.</creatorcontrib><creatorcontrib>Blute, Michael L.</creatorcontrib><creatorcontrib>Zincke, Horst</creatorcontrib><creatorcontrib>Bostwick, David G.</creatorcontrib><title>Predictors of cancer progression in T1a prostate adenocarcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk of cancer progression are needed to stratify patients for treatment. In the current study the authors attempted to identify such predictors of cancer progression in a large series of untreated patients with lengthy follow‐up.
METHODS
The authors studied 102 patients who were diagnosed with T1a prostate adenocarcinoma (incidental tumor involving ≤ 5% of the resected prostatic tissue) at the time they underwent transurethral resection of the prostate (TURP) at the Mayo Clinic between 1960–1970. None of these patients were treated. Patient ages ranged from 48–91 years (mean ± standard deviation, 69 ± 7 years). The average weight of the resected prostate tissue was 24 ±18 g (range, 3–115 g; median, 18 g). Tumor volume was measured by the grid method. Cox proportional hazards models were used to identify factors associated with cancer progression. Survival curves were estimated using the Kaplan‐Meier method.
RESULTS
Five‐year and 10‐year progression free survival rates were 93% and 87%, respectively. During the mean follow‐up of 9.5 ± 6.8 years (range, 0.3–31 years; median, 9.0 years), 14 patients developed clinical cancer progression, including 5 patients with systemic progression (1 with distant metastases and 4 who died of prostate adenocarcinoma). The interval from diagnosis to clinical cancer progression ranged from 1–23 years (mean, 7.3 years). The amount of resected prostate tissue (TURP weight) was associated with progression (P = 0.04). Patients with a TURP weight ≥ 30 g had 100% progression free survival at 10 years compared with a progression free survival rate of 73% in patients with a TURP weight < 12 g. Gleason score, tumor volume, number of chips involved by tumor, number of tumor foci, and the presence of high grade prostatic intraepithelial neoplasia were not significant in predicting cancer progression. There was a trend toward a worse prognosis with the increasing number of chips involved by cancer (P = 0.16). Patients with < 3 chips involved by cancer had a 88% 10‐year progression free survival rate compared with 73% in patients with ≥ 3 chips involved by cancer.
CONCLUSIONS
The clinical course of T1a prostate adenocarcinoma is variable. If left untreated, a small but significant proportion of patients are at risk for disease progression and death. However, the current study found that patients with a TURP weight ≥ 30 g have an excellent prognosis and can be managed conservatively. Cancer 1999;85:1300–4. © 1999 American Cancer Society.
The clinical course of patients with T1a prostate adenocarcinoma is variable. If left untreated, a small but significant proportion of patients are at risk for cancer progression and death. Patients with a transurethral resection tissue weight ≥ 30 g have an excellent prognosis and can be managed conservatively.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>incidental</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>natural history</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prognosis</subject><subject>progression</subject><subject>Prostate</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Survival Rate</subject><subject>T1a</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF2L1DAUQIMo7uzqX5CCIrsPHe9NJmkyyspQvwYWR3RFfbqkaSpdOu2azCD7703p-AEKPoUbTi4nh7EVwhwB-JPTD-tyfYZgihxwwU_RGAMC5ZmWS_UMBcByuVq_yMu35Xvk52IO83LzlOcPb7HZr1e32QwAdC4X4vMRO47xKo0Fl-IuO0JAbVDIGXv-Lvi6dbshxGxoMmd750N2HYavwcfYDn3W9tkl2vEq7uzOZ7b2_eBscG0_bO09dqexXfT3D-cJ-_jq5WX5Jr_YvF6Xq4vcCQE81wA1SMeN9k3NFecFcg1a2coIWyiuZCUl2EZp0QB6rdI3jMeq0Asvq0qJE_Z42ps8vu193NG2jc53ne39sI-kjFIC0CTw0wS6JByDb-g6tFsbbgiBxrpEY10aO9HYiX7WJS1J0ViXKNWlqS4JAio3xNPmBweFfbX19R97p5gJeHQAbHS2a0KK2cbfXJH8iiJhXybse9v5m7_0_m_3D7nDLH4Ag7mfwQ</recordid><startdate>19990315</startdate><enddate>19990315</enddate><creator>Cheng, Liang</creator><creator>Bergstralh, Erik J.</creator><creator>Scherer, Beth G.</creator><creator>Neumann, Roxann M.</creator><creator>Blute, Michael L.</creator><creator>Zincke, Horst</creator><creator>Bostwick, David G.</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990315</creationdate><title>Predictors of cancer progression in T1a prostate adenocarcinoma</title><author>Cheng, Liang ; Bergstralh, Erik J. ; Scherer, Beth G. ; Neumann, Roxann M. ; Blute, Michael L. ; Zincke, Horst ; Bostwick, David G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3302-800d05c298efd26227128086ab93a76265b550af683f01e861099e1b784e5bb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>incidental</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>natural history</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prognosis</topic><topic>progression</topic><topic>Prostate</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Survival Rate</topic><topic>T1a</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Bergstralh, Erik J.</creatorcontrib><creatorcontrib>Scherer, Beth G.</creatorcontrib><creatorcontrib>Neumann, Roxann M.</creatorcontrib><creatorcontrib>Blute, Michael L.</creatorcontrib><creatorcontrib>Zincke, Horst</creatorcontrib><creatorcontrib>Bostwick, David G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Liang</au><au>Bergstralh, Erik J.</au><au>Scherer, Beth G.</au><au>Neumann, Roxann M.</au><au>Blute, Michael L.</au><au>Zincke, Horst</au><au>Bostwick, David G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of cancer progression in T1a prostate adenocarcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1999-03-15</date><risdate>1999</risdate><volume>85</volume><issue>6</issue><spage>1300</spage><epage>1304</epage><pages>1300-1304</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk of cancer progression are needed to stratify patients for treatment. In the current study the authors attempted to identify such predictors of cancer progression in a large series of untreated patients with lengthy follow‐up.
METHODS
The authors studied 102 patients who were diagnosed with T1a prostate adenocarcinoma (incidental tumor involving ≤ 5% of the resected prostatic tissue) at the time they underwent transurethral resection of the prostate (TURP) at the Mayo Clinic between 1960–1970. None of these patients were treated. Patient ages ranged from 48–91 years (mean ± standard deviation, 69 ± 7 years). The average weight of the resected prostate tissue was 24 ±18 g (range, 3–115 g; median, 18 g). Tumor volume was measured by the grid method. Cox proportional hazards models were used to identify factors associated with cancer progression. Survival curves were estimated using the Kaplan‐Meier method.
RESULTS
Five‐year and 10‐year progression free survival rates were 93% and 87%, respectively. During the mean follow‐up of 9.5 ± 6.8 years (range, 0.3–31 years; median, 9.0 years), 14 patients developed clinical cancer progression, including 5 patients with systemic progression (1 with distant metastases and 4 who died of prostate adenocarcinoma). The interval from diagnosis to clinical cancer progression ranged from 1–23 years (mean, 7.3 years). The amount of resected prostate tissue (TURP weight) was associated with progression (P = 0.04). Patients with a TURP weight ≥ 30 g had 100% progression free survival at 10 years compared with a progression free survival rate of 73% in patients with a TURP weight < 12 g. Gleason score, tumor volume, number of chips involved by tumor, number of tumor foci, and the presence of high grade prostatic intraepithelial neoplasia were not significant in predicting cancer progression. There was a trend toward a worse prognosis with the increasing number of chips involved by cancer (P = 0.16). Patients with < 3 chips involved by cancer had a 88% 10‐year progression free survival rate compared with 73% in patients with ≥ 3 chips involved by cancer.
CONCLUSIONS
The clinical course of T1a prostate adenocarcinoma is variable. If left untreated, a small but significant proportion of patients are at risk for disease progression and death. However, the current study found that patients with a TURP weight ≥ 30 g have an excellent prognosis and can be managed conservatively. Cancer 1999;85:1300–4. © 1999 American Cancer Society.
The clinical course of patients with T1a prostate adenocarcinoma is variable. If left untreated, a small but significant proportion of patients are at risk for cancer progression and death. Patients with a transurethral resection tissue weight ≥ 30 g have an excellent prognosis and can be managed conservatively.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>10189135</pmid><doi>10.1002/(SICI)1097-0142(19990315)85:6<1300::AID-CNCR12>3.0.CO;2-#</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1999-03, Vol.85 (6), p.1300-1304 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69663019 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - surgery Aged Aged, 80 and over Biological and medical sciences Disease Progression Disease-Free Survival Humans incidental Male Medical sciences Middle Aged natural history Nephrology. Urinary tract diseases Prognosis progression Prostate Prostatectomy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Survival Rate T1a Tumors of the urinary system Urinary tract. Prostate gland |
| title | Predictors of cancer progression in T1a prostate adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T05%3A43%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20cancer%20progression%20in%20T1a%20prostate%20adenocarcinoma&rft.jtitle=Cancer&rft.au=Cheng,%20Liang&rft.date=1999-03-15&rft.volume=85&rft.issue=6&rft.spage=1300&rft.epage=1304&rft.pages=1300-1304&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19990315)85:6%3C1300::AID-CNCR12%3E3.0.CO;2-%23&rft_dat=%3Cproquest_cross%3E69663019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69663019&rft_id=info:pmid/10189135&rfr_iscdi=true |